Petros Pharmaceuticals amends Series A Preferred; maturity extended to Feb 2025, $500k cash covenant added

Petros Pharmaceuticals, Inc.

Extended maturity date of Series A Convertible Preferred Stock from prior date to February 15, 2025.
Deferred all unpaid accrued amounts under the Certificate of Designations to February 15, 2025.
Company must maintain at least $500,000 in unrestricted cash from January 15 to February 15, 2025.
Amended restrictive covenant to allow changes in sales strategy for Stendra avanafil and OTC switch platform.
Required holders waived any breach from failure to pay outstanding amounts as of January 23, 2025.

item 1.01 item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.4

Petros Pharmaceuticals, Inc.: Filed Certificate of Amendment related to Series A Preferred Stock.

Change: charter amendment

Exact text from the filing

The matters described in Item 1.01 of this Current Report on Form 8-K related to the Series A Preferred Stock and the filing of the Certificate of Amendment are incorporated herein by reference.

View on SEC.gov

Browse all governance changes →

Petros Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-005980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.